论文部分内容阅读
目的:探索PRL型垂体瘤患者血清中miRNA表达的差异。方法:先后采用miRNA基因芯片技术及实时荧光定量PCR技术检测PRL型垂体瘤患者和正常人群血清中的miRNA表达谱。结果:第1次筛选获得了28个PRL型垂体瘤相关miRNA,与正常人相比,有25个低表达,3个高表达;第2次验证筛选后,获得了3个差异性表达的miRNA,分别为:hsa-let-7e、hsa-miR-138、hsa-miR-26b。结论:血清中miRNA的异常表达参与了PRL型垂体瘤的发病机制。
Objective: To explore the difference of miRNA expression in serum of patients with PRL type pituitary adenoma. Methods: MiRNA microarray and real-time fluorescence quantitative PCR were used to detect the miRNA expression profile in serum of PRL type pituitary tumor patients and normal population. RESULTS: Twenty-eight PRL-type pituitary tumor-associated miRNAs were obtained in the first screening, compared with normal controls, 25 were low-expressed and 3 were highly expressed. After the second validation screening, 3 differentially expressed miRNAs , Respectively: hsa-let-7e, hsa-miR-138, hsa-miR-26b. Conclusion: The abnormal expression of miRNA in serum is involved in the pathogenesis of PRL type pituitary tumor.